Yesterday it was reported that the President & CEO of Amarin (AMRN), John Thero, exercised options to buy 191,997 AMRN shares at $1.56 a share, for a total transaction value of $300K.
Following John Thero’s last AMRN Buy transaction on December 04, 2017, the stock climbed by 12.4%. This recent transaction increases John Thero’s holding in the company by 9.65% to a total of $36.18 million.
See today’s analyst top recommended stocks >>
Based on Amarin’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $100 million and GAAP net loss of $1.81 million. In comparison, last year the company earned revenue of $52 million and had a GAAP net loss of $33.79 million. The company has a one-year high of $23.91 and a one-year low of $2.65. The Company has a Price to Book ratio of 40.5166.
Starting in November 2018, AMRN received 88 Buy ratings in a row. Seven different firms, including Cantor Fitzgerald and Citigroup, currently also have a Buy rating on the stock. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy AMRN with a $31 price target.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Read More on AMRN: